Half-year report · HY
4521.TEDINET S100X2PM
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥39.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥94.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥203m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥19.6bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥607m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥21.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.8bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥992m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥992m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥177.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥190.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥187.1bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥29.5bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥37.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥147.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥152.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥154.4bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥45.1bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥54.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥70.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥8.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥29.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥23.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥429m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥26.16 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥365.42 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥377.23 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 83.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Medicinereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥38.1bn |
| Medicinereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥38.1bn |
| Medicinereportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥479m |
| Real Estatereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Real Estatereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Real Estatereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥682m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥39.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥39.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥203m |
| Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥50.1bn |
| Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥50.1bn |
| Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥18.9bn |
| Real Estatereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Real Estatereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Real Estatereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥676m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥51.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥51.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥19.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 500
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 51372000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | 18903000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | 676000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 19579000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 19579000000 | JPY |
| Net sales of finished goods and merchandise | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | 37193000000 | JPY |
| Net sales of finished goods and merchandise | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Net sales of finished goods and merchandise | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 37193000000 | JPY |
| Net sales of finished goods and merchandise | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales of finished goods and merchandise | InterimDuration | 37193000000 | JPY |
| Royalty | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | 889000000 | JPY |
| Royalty | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Royalty | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 889000000 | JPY |
| Royalty | InterimDuration_ReconcilingItemsMember | － | JPY |
| Royalty | InterimDuration | 889000000 | JPY |
| Other income | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Other income | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | 1274000000 | JPY |
| Other income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1274000000 | JPY |
| Other income | InterimDuration_ReconcilingItemsMember | － | JPY |
| Other income | InterimDuration | 1274000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | 38082000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | 1274000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 39356000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 39356000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | 38082000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | 1274000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 39356000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration | 39356000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00935-000MedicineReportableSegmentsMember | -479000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00935-000RealEstateReportableSegmentsMember | 682000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 203000000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | InterimDuration | 203000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-13 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第106期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)科研製薬株式会社 | |
| Company name in english cover page | FilingDateInstant | KAKEN PHARMACEUTICAL CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 堀 内 裕 之 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |